397 related articles for article (PubMed ID: 24867993)
1. Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae.
Luther MK; Arvanitis M; Mylonakis E; LaPlante KL
Antimicrob Agents Chemother; 2014 Aug; 58(8):4612-20. PubMed ID: 24867993
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
Hall AD; Steed ME; Arias CA; Murray BE; Rybak MJ
Antimicrob Agents Chemother; 2012 Jun; 56(6):3174-80. PubMed ID: 22470111
[TBL] [Abstract][Full Text] [Related]
3. Activities of fosfomycin and rifampin on planktonic and adherent Enterococcus faecalis strains in an experimental foreign-body infection model.
Oliva A; Furustrand Tafin U; Maiolo EM; Jeddari S; Bétrisey B; Trampuz A
Antimicrob Agents Chemother; 2014; 58(3):1284-93. PubMed ID: 24145537
[TBL] [Abstract][Full Text] [Related]
4. Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model.
LaPlante KL; Rybak MJ; Leuthner KD; Chin JN
Antimicrob Agents Chemother; 2006 Apr; 50(4):1298-303. PubMed ID: 16569844
[TBL] [Abstract][Full Text] [Related]
5. Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis.
LaPlante KL; Woodmansee S
Antimicrob Agents Chemother; 2009 Sep; 53(9):3880-6. PubMed ID: 19564363
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of daptomycin combined with fosfomycin or rifampin on planktonic and adherent linezolid-resistant isolates of Enterococcus faecalis.
Zheng JX; Sun X; Lin ZW; Qi GB; Tu HP; Wu Y; Jiang SB; Chen Z; Deng QW; Qu D; Yu ZJ
J Med Microbiol; 2019 Mar; 68(3):493-502. PubMed ID: 30882300
[TBL] [Abstract][Full Text] [Related]
7. Measurement of ampicillin, vancomycin, linezolid and gentamicin activity against enterococcal biofilms.
Sandoe JA; Wysome J; West AP; Heritage J; Wilcox MH
J Antimicrob Chemother; 2006 Apr; 57(4):767-70. PubMed ID: 16464896
[TBL] [Abstract][Full Text] [Related]
8. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.
LaPlante KL; Rybak MJ
Antimicrob Agents Chemother; 2004 Dec; 48(12):4665-72. PubMed ID: 15561842
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of oritavancin alone and in combination against vancomycin-susceptible and -resistant enterococci in an in-vivo Galleria mellonella survival model.
Meyer KA; Deraedt MF; Harrington AT; Danziger LH; Wenzler E
Int J Antimicrob Agents; 2019 Aug; 54(2):197-201. PubMed ID: 31034937
[TBL] [Abstract][Full Text] [Related]
10. In vitro analysis of resistance selection by linezolid in vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium.
Allen GP; Bierman BC
Int J Antimicrob Agents; 2009 Jul; 34(1):21-4. PubMed ID: 19243921
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations.
Tsuji BT; Bulitta JB; Brown T; Forrest A; Kelchlin PA; Holden PN; Peloquin CA; Skerlos L; Hanna D
J Antimicrob Chemother; 2012 Sep; 67(9):2182-90. PubMed ID: 22685161
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.
Hall Snyder A; Werth BJ; Barber KE; Sakoulas G; Rybak MJ
J Antimicrob Chemother; 2014 Aug; 69(8):2148-54. PubMed ID: 24777900
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).
Lee DK; Kim Y; Park KS; Yang JW; Kim K; Ha NJ
J Biochem Mol Biol; 2007 Nov; 40(6):881-7. PubMed ID: 18047782
[TBL] [Abstract][Full Text] [Related]
14. Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in an
Jahanbakhsh S; Singh NB; Yim J; Kebriaei R; Smith JR; Lev K; Tran TT; Rose WE; Arias CA; Rybak MJ
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094136
[No Abstract] [Full Text] [Related]
15. Antibiotic regimens with rifampicin for treatment of Enterococcus faecium in biofilms.
Holmberg A; Rasmussen M
Int J Antimicrob Agents; 2014 Jul; 44(1):78-80. PubMed ID: 24837415
[TBL] [Abstract][Full Text] [Related]
16. Time-kill study and synergistic activity of cell-wall inhibitor antibiotics in combination with gentamicin against Enterococcus faecalis and Enterococcus faecium.
Aligholi M; Emaneini M; Taherikalani M; Shahsavan S; Jabalameli F; Asadollahi P; Khoramian B; Eslampour MA
Acta Microbiol Immunol Hung; 2011 Sep; 58(3):219-26. PubMed ID: 21983323
[TBL] [Abstract][Full Text] [Related]
17. In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin.
Pankey G; Ashcraft D; Patel N
Antimicrob Agents Chemother; 2005 Dec; 49(12):5166-8. PubMed ID: 16304195
[TBL] [Abstract][Full Text] [Related]
18. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species.
DeRyke CA; Sutherland C; Zhang B; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2006 Nov; 50(11):3529-34. PubMed ID: 17065618
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
Barber KE; Smith JR; Raut A; Rybak MJ
J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
